Mariner
CNTX icon

Mariner’s Context Therapeutics CNTX Stock Holding History

Mariner’s Portfolio CNTX Stock Details CNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$8.59K Buy
+28,579
New +$14.1K ﹤0.01% 3459

Other funds holding CNTX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $85.7B AUM 51.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $73.4B AUM 32.8% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $463B AUM

Mariner's CNTX Position: Q3 2026 in Review

Mariner opened a new position in Context Therapeutics (CNTX) in Q3 2026: 28,579 shares worth $8.59K. The stake represents ﹤0.01% of the portfolio and ranks #3459 among its holdings.

59 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

  • Mariner held 28,579 shares of Context Therapeutics worth $8.59K as of Q3 2026.
  • Context Therapeutics was a new Mariner position in Q3 2026.
  • Context Therapeutics made up ﹤0.01% of Mariner's portfolio in Q3 2026, its #3459 holding.
  • 59 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Mariner's 13F filing for Q3 2026, filed 12 Nov 2026.